Intrinsic disorder in PTEN and its interactome confers structural plasticity and functional versatility

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Malaney, Prerna ^a   Pathak, Ravi Ramesh ^a   Xue, Bin ^a   Uversky, Vladimir N ^a,c,d   Davé, Vrushank ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d INSTITUTE FOR BIOLOGICAL INSTRUMENTATION   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; BINDING SITE; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; GENE REGULATORY NETWORK; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; MUTATION; NEOPLASM; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN MOTIF; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; GENE REGULATORY NETWORKS; HUMANS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASMS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN INTERACTION MAPS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PTEN PHOSPHOHYDROLASE; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION;

EID: 84879619834     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep02035     Document Type: Article

References (67)

1. Uversky, V. N., Oldfield, C. J. & Dunker, A. K. Intrinsically disordered proteins in human diseases: introducing the D2 concept. Annu Rev Biophys 37, 215-246 (2008).
2. Ward, J. J., Sodhi, J. S., McGuffin, L. J., Buxton, B. F. & Jones, D. T. Prediction and functional analysis of native disorder in proteins from the three kingdoms of life. Journal of Molecular Biology 337, 635-645 (2004). (Pubitemid 38326883)
3. Dunker, A. K. et al. Intrinsically disordered protein. JMol GraphModel 19, 26-59 (2001). (Pubitemid 32411501)
4. Fong, J. H., Shoemaker, B. A. & Panchenko, A. R. Intrinsic protein disorder in human pathways. Mol Biosyst 8, 320-326 (2012).
5. Gsponer, J. & Babu, M. M. The rules of disorder or why disorder rules. Prog Biophys Mol Biol 99, 94-103 (2009).
6. Iakoucheva, L. M., Brown, C. J., Lawson, J. D., Obradovic, Z. & Dunker, A. K. Intrinsic disorder in cell-signaling and cancer-associated proteins. Journal of Molecular Biology 323, 573-584 (2002). (Pubitemid 35283681)
7. Babu, M. M., van der Lee, R., de Groot, N. S. & Gsponer, J. Intrinsically disordered proteins: regulation and disease. Curr Opin Struct Biol 21, 432-440 (2011).
8. Song, M. S., Salmena, L. & Pandolfi, P. P. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol advance online publication (2012).
9. Zoncu, R., Efeyan, A. & Sabatini, D. M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12, 21-35 (2011).
10. Vivanco, I. & Sawyers, C. L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2, 489-501 (2002). (Pubitemid 37328931)
11. Sansal, I. & Sellers, W. R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22, 2954-2963 (2004). (Pubitemid 41079915)
12. Maehama, T. & Dixon, J. E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273, 13375-13378 (1998). (Pubitemid 28268370)
13. Zhang, X. C., Piccini, A., Myers, M. P., Van Aelst, L. & Tonks, N. K. Functional Analysis of the Protein Phosphatase Activity of PTEN. Biochem J (2012).
14. Hollander,M. C., Blumenthal, G. M. & Dennis, P. A. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 11, 289-301 (2011).
15. Leslie, N. R. & Foti, M. Non-genomic loss of PTEN function in cancer: not in my genes. Trends in Pharmacological Sciences 32, 131-140 (2011).
16. Das, S., Dixon, J. E. & Cho, W. Membrane-binding and activation mechanism of PTEN. Proc Natl Acad Sci USA 100, 7491-7496 (2003). (Pubitemid 36759997)
17. Lee, J. O. et al. Crystal structure of the PTEN tumor suppressor: Implications for its phosphoinositide phosphatase activity and membrane association. Cell 99, 323-334 (1999).
18. Rahdar, M. et al. A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN. Proc Natl Acad Sci USA 106, 480-485 (2009).
19. Vazquez, F., Ramaswamy, S., Nakamura, N. & Sellers, W. R. Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol 20, 5010-5018 (2000). (Pubitemid 30431555)
20. Ross, A. H. & Gericke, A. Phosphorylation keeps PTEN phosphatase closed for business. Proc Natl Acad Sci USA 106, 1297-1298 (2009).
21. Odriozola, L., Singh, G., Hoang, T. & Chan, A. M. Regulation of PTEN activity by its carboxyl-terminal autoinhibitory domain. J Biol Chem 282, 23306-23315 (2007). (Pubitemid 47311930)
22. Xue, B., Dunbrack, R. L., Williams, R. W., Dunker, A. K. & Uversky, V. N. PONDR-FIT: a meta-predictor of intrinsically disordered amino acids. Biochim Biophys Acta 1804, 996-1010 (2010).
23. Romero, P. et al. Sequence complexity of disordered protein. Proteins 42, 38-48 (2001).
24. Vacic, V.,Uversky, V. N.,Dunker, A. K. & Lonardi, S. Composition Profiler: a tool for discovery and visualization of amino acid composition differences. BMC Bioinformatics 8, 211 (2007).
25. Stenson, P. D. et al. The Human Gene Mutation Database: 2008 update. Genome Med 1, 13 (2009).
26. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2, 401-404 (2012).
27. Gao, J. J. et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. Science Signaling 6, (2013).
28. Kuntzer, J., Eggle, D., Lenhof, H. P., Burtscher, H. & Klostermann, S. The Roche Cancer Genome Database (RCGDB). Hum Mutat 31, 407-413 (2010).
29. Mosca, R., Pache, R. A. & Aloy, P. The Role of Structural Disorder in the Rewiring of Protein Interactions through Evolution. Mol Cell Proteomics 11, M111 014969 (2012).
30. Liu, J., Tan, H.& Rost, B. Loopy proteins appear conserved in evolution. JMol Biol 322, 53-64 (2002). (Pubitemid 36132670)
31. Schlessinger, A. et al. Protein disorder-a breakthrough invention of evolution? Curr Opin Struct Biol 21, 412-418 (2011).
32. Espinoza-Fonseca, L. M. Aromatic residues link binding and function of intrinsically disordered proteins. Molecular BioSystems 8, 237-246 (2012).
33. Dyson, H. J. & Wright, P. E. Coupling of folding and binding for unstructured proteins. Current Opinion in Structural Biology 12, 54-60 (2002). (Pubitemid 34142721)
34. Fong, J. H. et al. Intrinsic Disorder in Protein Interactions: Insights From a Comprehensive Structural Analysis. PLoS Comput Biol 5, e1000316 (2009).
35. Dunker, A. K., Cortese, M. S., Romero, P., Iakoucheva, L. M. & Uversky, V. N. Flexible nets. FEBS Journal 272, 5129-5148 (2005).
36. Shimizu, K. & Toh, H. Interaction between Intrinsically Disordered Proteins Frequently Occurs in a Human Protein-Protein Interaction Network. Journal of Molecular Biology 392, 1253-1265 (2009).
37. HK, L., L, W., YC, H., S,A.&C, C. Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J 21, 4037-4048 (2002).
38. Tang, J. et al. Critical role for Daxx in regulating Mdm2. Nat Cell Biol 8, 855-862 (2006). (Pubitemid 44151589)
39. Lin, D.-Y. et al. Negative Modulation of Androgen Receptor Transcriptional Activity by Daxx. Molecular and Cellular Biology 24, 10529-10541 (2004). (Pubitemid 39603115)
40. Yeh, S. et al. Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. Proceedings of the National Academy of Sciences 97, 11256-11261 (2000).
41. Dubrovska, A. et al. TGF[beta]1//Smad3 counteracts BRCA1-dependent repair of DNA damage. 24, 2289-2297 (2005).
42. Yam, C. H. et al. MDM2 and MDMX Inhibit the Transcriptional Activity of Ectopically Expressed SMAD Proteins. Cancer Research 59, 5075-5078 (1999). (Pubitemid 29503961)
43. Cui, Q. et al. A map of human cancer signaling. Mol Syst Biol 3, 152 (2007).
44. Awan, A. et al. Regulatory network motifs and hotspots of cancer genes in a mammalian cellular signalling network. IET Syst Biol 1, 292-297 (2007). (Pubitemid 47354627)
45. Li, L. et al. The human phosphotyrosine signaling network: evolution and hotspots of hijacking in cancer. Genome Res 22, 1222-1230 (2012).
46. Newman, R. H. et al. Construction of human activity-based phosphorylation networks. Mol Syst Biol 9, 655 (2013).
47. Mohan, A. et al. Analysis of molecular recognition features (MoRFs). J Mol Biol 362, 1043-1059 (2006). (Pubitemid 44353519)
48. Disfani, F. M. et al. MoRFpred, a computational tool for sequence-based prediction and characterization of short disorder-to-order transitioning binding regions in proteins. Bioinformatics 28, 175-183 (2012).
49. Diella, F. et al. Understanding eukaryotic linear motifs and their role in cell signaling and regulation. Frontiers in Bioscience 13, 6580-6603 (2008).
50. Dinkel, H. et al. ELM-the database of eukaryotic linear motifs. Nucleic Acids Res 40, D242-D251 (2012).
51. Singh, G. & Chan, A. M. Post-translational modifications of PTEN and their potential therapeutic implications. Curr Cancer Drug Targets 11, 536-547 (2011).
52. Cordier, F. et al. Ordered phosphorylation events in two independent cascades of the PTEN C-tail revealed by NMR. J Am Chem Soc (2012).
53. Gao, J. X. D. Correlation between posttranslational modification and intrinsic disorder in protein. Pac Symp Biocomput. 94-103 (2012).
54. Iakoucheva, L. M. et al. The importance of intrinsic disorder for protein phosphorylation. Nucleic Acids Res 32, 1037-1049 (2004). (Pubitemid 38854704)
55. Salmena, L., Carracedo, A. & Pandolfi, P. P. Tenets of PTEN tumor suppression. Cell 133, 403-414 (2008). (Pubitemid 351622014)
56. Rahdar, M. Johns Hopkins University School of Medicine (2011).
57. Rotea, W., Jr. & Saad, E. D. Targeted drugs in oncology: new names, new mechanisms, new paradigm. Am J Health Syst Pharm 60, 1233-1243; quiz 1244-1235 (2003).
58. Pearson, M. A. & Fabbro, D. Targeting protein kinases in cancer therapy: a success? Expert Rev Anticancer Ther 4, 1113-1124 (2004). (Pubitemid 39646565)
59. Metallo, S. J. Intrinsically disordered proteins are potential drug targets. CurrOpin Chem Biol 14, 481-488 (2010).
60. Uversky, V. N. Intrinsically disordered proteins and novel strategies for drug discovery. Expert Opinion on Drug Discovery 7, 475-488 (2012).
61. Tzakos, A. G. Intrinsic Protein Disorder as a Drug Target in Oncology: Designing Drugs Targeting Plasticity. Biochemistry and Pharmacology (2012).
62. Blundell, T. L. et al. Protein-protein interactions in receptor activation and intracellular signalling. Biol Chem 381, 955-959 (2000).
63. Chene, P. Inhibition of the p53-MDM2 interaction: Targeting a protein-protein interface. Molecular Cancer Research 2, 20-28 (2004). (Pubitemid 38167104)
64. del Sol, A., Balling, R., Hood, L. & Galas, D. Diseases as network perturbations. Curr Opin Biotech 21, 566-571 (2010).
65. Gsponer, J., Futschik, M. E., Teichmann, S. A. & Babu, M. M. Tight regulation of unstructured proteins: from transcript synthesis to protein degradation. Science 322, 1365-1368 (2008). (Pubitemid 352775246)
66. Deeds, E. J., Krivine, J., Feret, J., Danos, V. & Fontana, W. Combinatorial complexity and compositional drift in protein interaction networks. PLoS One 7, e32032 (2012).
67. Lopez, F. et al. TranscriptomeBrowser: A Powerful and Flexible Toolbox to Explore Productively the Transcriptional Landscape of the Gene Expression Omnibus Database. PLoS One 3, e4001 (2008).